Elekta: New Leksell Gamma Knife to benefit more patients with brain disease
April 25 2015 - 4:42AM
Business Wire
Elekta introduces latest in cranial radiosurgery at 3rd ESTRO
Forum
Regulatory News:
With the introduction of Elekta’s new Leksell Gamma Knife®
Icon™, the benefits of precision cranial radiosurgery are now
available for more patients with a wider variety of tumor types and
sizes. This latest generation stereotactic radiosurgery system for
the brain, integrates advanced motion management, dose delivery and
imaging technologies, significantly increasing the versatility of
Gamma Knife radiosurgery. Elekta unveiled Leksell Gamma Knife Icon
today at the 3rd ESTRO Forum in Barcelona.
“This is great news for patients,” says Niklas Savander, Elekta
President and CEO. “With the new functionality in Leksell Gamma
Knife Icon, doctors will have even greater flexibility in how
radiosurgery is delivered, in addition to more assurance about the
radiation dose and how accurately it’s targeted. This new Leksell
Gamma Knife will further strengthen our leading position in
radiosurgery and hopefully address some of the more complex brain
disorders from which many people suffer.”
Icon provides this increased flexibility by allowing physicians
to choose either frame-based or frameless methods to immobilize the
patient’s head, in addition to the option to perform the treatment
in a single session or multiple sessions (fractions or
hypofractionation). The system even enables clinicians to choose
the degree of precision needed for each patient’s case – ranging
from traditional radiosurgery accuracy to ultra-precise
microradiosurgery.
“With Leksell Gamma Knife Icon, we expect two major changes,”
says Professor Jean Régis, a neurosurgeon and Gamma Knife program
director at University Hospital La Timone (Marseilles, France).
“First, the system will increase indications, in the sense that we
will be able do more hypofractionation. The second great benefit of
Icon is the ability to do true adaptive radiosurgery both
interfraction and intrafraction. It has the capacity to detect and
measure position changes – to automatically propose dose planning
adaptation – while providing the operator with an estimate of the
influence of these corrections for validation."
Elekta developed Icon to be the preferred modality to treat
almost any intracranial target. It offers new functionality
familiar to radiation oncologists, such as cone beam CT, which
should help increase the adoption of radiosurgery. By being
attractive to more clinics, more patients will have access to the
benefits of precision cranial radiosurgery.
Maurits Wolleswinkel, Executive Vice President Neuroscience at
Elekta, says: “By giving doctors greater clinical flexibility and
precision, it should also give patients greater confidence and
peace of mind. This system is intended to give physicians the
ability and confidence to treat virtually any pathology found in
the brain with the highest precision and certainty, and the
efficient workflows that will allow them to do this every day in
the clinic,” he says.
Leksell Gamma Knife Icon is not for sale or distribution in the
US and is not CE marked.
For further information, please contact:
Gert van Santen, Group Vice President Corporate Communications,
Elekta ABTel: +31 653 561 242, e-mail:
gert.vansanten@elekta.comTime zone: CET: Central European Time
Tobias Bülow, Director Financial Communication, Elekta ABTel:
+46 722 215 017, e-mail: tobias.bulow@elekta.comTime
zone: CET: Central European Time
The above information is such that Elekta AB (publ) shall make
public in accordance with the Securities Market Act and/or the
Financial Instruments Trading Act. The information was published at
10:15 CET on April 25, 2015.
About Elekta
Elekta is a human care company pioneering significant
innovations and clinical solutions for treating cancer and brain
disorders. The company develops sophisticated, state-of-the-art
tools and treatment planning systems for radiation therapy,
radiosurgery and brachytherapy, as well as workflow enhancing
software systems across the spectrum of cancer care. Stretching the
boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both health
care providers and patients, Elekta aims to improve, prolong and
even save patient lives.
Today, Elekta solutions in oncology and neurosurgery are used in
over 6,000 hospitals worldwide. Elekta employs around 3,800
employees globally. The corporate headquarters is located in
Stockholm, Sweden, and the company is listed on NASDAQ Stockholm.
Website: www.elekta.com.
This information was brought to you by Cision
http://news.cision.com
Elekta ABGert van Santen, +31 653 561 242Group Vice President
Corporate Communicationsgert.vansanten@elekta.comorTobias Bülow,
+46 722 215 017Director Financial
Communicationtobias.bulow@elekta.com